Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation

Autor:	Concepción Andón Saavedra, Goretti Vázquez Vázquez, Victor Noriega Concepción, Andrea Galego García, Rosario Varela Gómez
Rok vydání:	2017
Předmět:	Adult Male congenital hereditary and neonatal diseases and abnormalities High dose dexamethasone medicine.medical_treatment Pure red cell aplasia Hematopoietic stem cell transplantation 030204 cardiovascular system & hematology Red-Cell Aplasia Pure lcsh:RC254-282 ABO Blood-Group System 03 medical and health sciences 0302 clinical medicine ABO blood group system hemic and lymphatic diseases medicine Humans Aplastic anemia Dexamethasone Immunosuppression Therapy business.industry lcsh:RC633-647.5 Incidence (epidemiology) Hematopoietic Stem Cell Transplantation Anemia Aplastic Immunosuppression Hematology General Medicine lcsh:Diseases of the blood and blood-forming organs medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Allografts Oncology Immunology business 030215 immunology medicine.drug
Zdroj:	Hematology/Oncology and Stem Cell Therapy, Vol 11, Iss 1, Pp 44-46 (2018)
ISSN:	2589-0646
Popis:	The literature reports an incidence of Pure Red Cell Aplasia (PRCA) ranging from 6-30% of all cases of ABO-incompatible HSCT. Although most patients resolve spontaneously after withdrawal immunosuppression, some of them require more aggressive treatment to manage this condition. Keywords: Pure red cell aplasia, Aplastic anemia, Hematopoietic stem cell transplantation, Dexamethasone
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d0a84fd0ac9278dc6d98761b2337edc https://pubmed.ncbi.nlm.nih.gov/29079126 Zobrazit plný text záznamu